Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion

1. Ono Pharmaceutical, a Japanese pharmaceutical company, has announced its plans to acquire Deciphera Pharmaceuticals, a US-based biotechnology firm, for $2.4 billion.
2. The acquisition aims to strengthen Ono's oncology pipeline by incorporating Deciphera's portfolio of kinase inhibitors, which are used in the treatment of various types of cancer.
3. Deciphera's lead product, QINLOCK (ripretinib), is a switch-control kinase inhibitor approved for the treatment of advanced gastrointestinal stromal tumors (GIST).
4. Ono Pharmaceutical has been actively seeking strategic collaborations and acquisitions to expand its global presence and enhance its drug development capabilities in the oncology space.
5. The acquisition of Deciphera Pharmaceuticals will provide Ono with access to a broader range of cancer treatments and a more extensive clinical development pipeline.
6. The transaction is expected to close in the second half of 2023, subject to regulatory approvals and customary closing conditions.
7. Upon completion of the acquisition, Deciphera Pharmaceuticals will become a wholly-owned subsidiary of Ono Pharmaceutical.
8. The combined entity will have a strong focus on developing innovative cancer therapies and addressing unmet medical needs in the global market.